Cubist Pharmaceuticals (CBST) says it's initiating Phase 3 efficacy studies of bevenopran in...

|By:, SA News Editor

Cubist Pharmaceuticals (CBST) says it's initiating Phase 3 efficacy studies of bevenopran in patients with chronic non-cancer pain and opioid-induced constipation. The program includes three identically-designed studies that will enroll approximately 600 patients each designed to evaluate the drug's efficacy and safety, and includes a 1,400-patient one-year, placebo-controlled safety study which was initiated in October 2012.